CT83 and liver cancer: Subsequently, we will expand the sample size for further stratified analysis, and extend the follow-up period to confirm that the expression of KK-LC-1 can be used as an effective biomarker for predicting efficacy and prognosis of the liver cancer patients with immunotherapy.